Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov-Dec;25(11-12):535-8.
doi: 10.1007/s10815-008-9276-4. Epub 2008 Nov 18.

Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease

Foad Azem  1 , Nivin Samara, Tanya Cohen, Dalit Ben-Yosef, Beni Almog, Joseph B Lessing, Odeliya Goor, Ami Amit
Affiliations

Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease

Foad Azem et al. J Assist Reprod Genet. 2008 Nov-Dec.

Abstract

Purpose: To examine ovarian reserve following chemotherapy in women with Hodgkin's disease.

Methods: The study included nine patients who underwent ovarian tissue cryopreservation (OTCP) prior to chemotherapy consisting of the ABVD regimen (Adriamycin, bleomycin, vinblastine, and dacarbazine) and co-treatment with gonadotropin-releasing hormone agonist (GnRH-a) (Group A), and 13 patients treated by the ABVD protocol only without GnRH-a (Group B). The average age was 25.2 +/- 2.7 years for the women in Group A and 31.8 +/- 6.8 years for those in Group B.

Results: Six months following the end of chemotherapy, the menstrual cycle resumed in all Group A patients and in four Group B patients who had amenorrhea. Eight Group B patients had regular menses during and after chemotherapy. None of the patients suffered from ovarian failure. Two Group A patients conceived in the first year after completing chemotherapy.

Conclusions: Co-treatment with GnRH-a has little effect on ovarian protection in women with Hodgkin's disease.

PubMed Disclaimer

References

    1. Kogel KE, Sweetenham JW. Current therapies in Hodgkin’s disease. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S19–27. - PubMed
    1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478. - PubMed
    1. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med. 1997;29:199–206. doi:10.3109/07853899708999337. - DOI - PubMed
    1. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol. 1987;19:159–62. doi:10.1007/BF00254570. - DOI - PubMed
    1. Oktay K, Sonmerz M. Ovarian tissue banking, not just ovarian cryopreservation. Hum Reprod. 2004;19:477–80. doi:10.1093/humrep/deh152. - DOI - PubMed

MeSH terms

Supplementary concepts